参考文献/References:
[1] Wisplinghoff H,Bischoff T,Tallent S M,et al.Nosocomial bloodstream infections in US hospitals:analysis of 24 179 cases from a prospectivenationwide surveillance study[J].Clin Infect Dis,2004,39(3):309-317.
[2] Bouza E,Munoz P.Epidemiology of candidemia in intensive care units[J].Int J Antimicrob Agents,2008,32(Suppl 2):S87-S91.
[3] Falagas ME,Roussos N,Vardakas KZ.Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients invarious parts of the world:a systematic review[J].Int J Infect Dis,2010,14(11):e954-e966.
[4] Rex JH,Pfaller MA,Galgiani JN,et al.Development of interpretive breakpoints for antifungal susceptibility testing:conceptual framework and analysisof in vitro-in vivo correlation data for fluconazole,itraconazole,and candidainfections.Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards[J].Clin Infect Dis,1997,24(2):235-247.
[5] Pfaller MA,Castanheira M,Lockhart SR,et al.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata[J].J Clin Microbiol,2012,50(4):1199-1203.
[6] Pfaller M,Boyken L,Hollis R,et al.Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin,caspofungin,and micafungin[J].J Clin Microbiol,2011,49(2):624-629.
[7] Posteraro B,Sanguinetti M.The future of fungal susceptibility testing[J].Future Microbiol,2014,9(8):947-967.
[8] de Carolis E,Vella A,Florio AR,et al.Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species[J].J Clin Microbiol,2012,50(7):2479-2483.
[9] Vella A,De Carolis E,Vaccaro L,et al.Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flightmass spectrometry analysis[J].J Clin Microbiol,2013,51(9):2964-2969.
[10] Perlin DS.Antifungal drug resistance: do molecular methods provide a way forward?[J].Curr Opin Infect Dis,2009,22(6):568-573.
[11] Garnaud C,Botterel F,Sertour N,et al.Next-generation sequencing offers new insights into the resistance of Candida spp.To echinocandins and azoles[J].Journal of Antimicrobial Chemotherapy,2015,70(9):2556-2565.
[12] Xiao M,Fan X,Chen SC,et al.Antifungal susceptibilities of Candida glabrata species complex,Candida krusei,Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China:3 year national surveillance[J].J Antimicrob Chemother,2015,70(3):802-810.
[13] Kanafani ZA,Perfect JR.Antimicrobial resistance:resistance to antifungal agents: mechanisms and clinical impact[J].Clin Infect Dis,2008,46(1):120-128.
[14] Vale-Silva L,Ischer F,Leibundgut-Landmann S,et al.Gain-of-function mutations in PDR1,a regulator of antifungal drug resistance in Candida glabrata,control adherence to host cells[J].Infect Immun,2013,81(5):1709-1720.
[15] Garcia-Effron G,Katiyar SK,Park S,et al.A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis,Candida orthopsilosis,and Candida metapsilosis accounts for reduced echinocandin susceptibility[J].Antimicrob Agents Chemother,2008,52(7):2305-2312.
[16] Sun HY,Singh N.Characterisation of breakthrough invasive mycoses in echinocandin recipients:an evidence-based review[J].Int J Antimicrob Agents,2010,35(3):211-218.
[17] Jensen RH,Johansen HK,Arendrup MC.Stepwise development of a homozygous S80P substitution in Fks1p,conferring echinocandin resistance in Candidatropicalis[J].Antimicrob Agents Chemother,2013,57(1):614-617.
[18] Duran-Valle MT,Gago S,Gomez-Lopez A,et al.Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin[J].Antimicrob Agents Chemother,2012,56(6):3417-3419.
[19] Lee KK,Maccallum DM,Jacobsen MD,et al.Elevated cell wall chitin inCandida albicans confers echinocandin resistance in vivo[J].Antimicrob Agents Chemother,2012,56(1):208-217.
[20] Shields RK,Nguyen MH,Press EG,et al.The presence of an FKS mutationrather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata[J].Antimicrob Agents Chemother,2012,56(9):4862-4869.
[21] Beyda ND,Lewis RE,Garey KW.Echinocandin resistance in Candida species:mechanisms of reduced susceptibility and therapeutic approaches[J].AnnPharmacother,2012,46(7/8):1086-1096.
[22] Florent M,Noel T,Ruprich-Robert G, et al.Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae[J].Antimicrob Agents Chemother,2009,53(7):2982-2990.
[23] Cuenca-Estrella M, Diaz-Guerra TM, Mellado E,et al.Detection of resistance to amphotericin B in Candida isolates by using Iso-Sensitest broth[J].Antimicrob Agents Chemother,2001,45(7):2070-2074.
[24] Pfaller MA,Espinel-Ingroff A,Canton E,et al.Wi-ld-type MIC distributions and epidemiological cutoff values for amphotericin B,flucytosine,and itraconazole and Candida spp.as determined by CLSI broth microdilution[J].J Clin Microbiol,2012,50(6):2040-2046.
[25] Vincent BM, Lancaster AK, Scherz-Shouval R,et al.Fitness trade-offs restrict the evolution of resistance to amphotericin B[J].PLoS Biol,2013,11(10):e1001692.
[26] Taff HT, Mitchell KF, Edward JA,et al.Mechanisms of Candida biofilm drug resistance[J].Future Microbiol,2013,8(10):1325-1337.
[27] Pfaller MA,Messer SA,Woosley LN,et al.Echi-nocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011:application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporaltrends of antifungal resistance[J].J Clin Microbiol,2013,51(8):2571-2581.
[28] Pfaller MA,Diekema DJ,Gibbs DL,et al.Results from the artemis DISK global antifungal surveillance study,1997 to 2007:a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion[J].J Clin Microbiol,2010,48(4):1366-1377.